COMMUNIQUÉS West-GlobeNewswire

Lisata Therapeutics Provides Update Following Termination of Merger Agreement
04/08/2026
Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders Lisata’s Board of Directors and management continues to evaluate strategic [...]
TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director
04/08/2026
MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced [...]
Grey Matters Announces September Opening of its First Brain Dedicated PET Neuroimaging Clinic in the U.S.
04/08/2026
VANCOUVER, British Columbia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company” or “ Grey Matters ”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to [...]
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
04/08/2026
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data [...]
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
04/08/2026
Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b monotherapy trial [...]
Certara Reports Second Quarter 2026 Financial Results
04/08/2026
A ppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance [...]
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
04/08/2026
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms DNTH312 demonstrated [...]
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
04/08/2026
NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the market closes on Monday [...]
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
04/08/2026
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive [...]
Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
04/08/2026
Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE NEWSWIRE [...]
Vantage Biosciences Completes Enrollment in Phase 2 SeeClear Study of Oral Oruvestat in Non-Proliferative Diabetic Retinopathy
04/08/2026
LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Vantage Biosciences today announced that it has completed patient enrollment in the Phase 2 SeeClear study (VX01-DR-201) of oruvestat (VX-01), an investigational, orally [...]
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
04/08/2026
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
04/08/2026
-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon -- -- Management to host conference call to discuss second quarter 2026 financial results [...]
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
04/08/2026
Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer , taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal clinical trials and [...]
Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
04/08/2026
LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat [...]
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
04/08/2026
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines Neflamapimod selected for the ILAP by joint consensus [...]
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
04/08/2026
NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments [...]
Transactions in connection with share buy-back program
04/08/2026
Company announcement no. 28 - 26 04 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
AMSilk collaboration: Biotech silk protein yarns feature in Balenciaga 55th Couture Collection
04/08/2026
Haute Couture evening gown constructed using AMSilk-blend fabric Follows debut of AMSilk bioengineered silk protein yarns in Balenciaga Spring Collection 2026 NEURIED, Germany, Aug. 04, 2026 (GLOBE NEWSWIRE) -- AMSilk, [...]

Pages